Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lokuta, M. A.
Right arrow Articles by Shin, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lokuta, M. A.
Right arrow Articles by Shin, H. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 23, Issue of June 7, 1996 pp. 13731-13738
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Mechanisms of Murine RANTES Chemokine Gene Induction by Newcastle Disease Virus*

(Received for publication, January 18, 1996, and in revised form, March 8, 1996)

Mary A. Lokuta Dagger §, Joseph Maher par , Katherine H. Noe Dagger , Paula M. Pitha , Moon L. Shin Dagger '' and Hyun S. Shin '''

From the Dagger  Department of Pathology, University of Maryland, School of Medicine, Baltimore, Maryland 21201 and the  Department of Molecular Biology and Genetics, The Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

We have previously defined the lipopolysaccharide (LPS)-responsive element (LRE) in the promoters of murine RANTES (regulated on activation normal T-cell expressed) (MuRantes) and murine IP-10/crg-2, chemokines which have potent chemotactic properties for inflammatory cells including monocytes and T lymphocytes. In the present work, we studied the transcriptional mechanism of MuRantes gene induction by virus and compared it with that of LPS in an effort to understand the host responses to virus and bacterial toxins at the molecular level. MuRantes mRNA expression is induced by Newcastle disease virus (NDV) and LPS in the RAW 264.7 macrophage cell line and peritoneal macrophages of LPS-responsive C3HeB/FeJ mice. In LPS-hyporesponsive C3H/HeJ mice, only NDV induces this chemokine gene, indicating that the pathways of transcriptional activation by NDV and LPS are not identical. Using a transient transfection assay, the minimal virus-responsive element (VRE) was localized between nt -175 and -116. The VRE contains previously defined LRE motif 1 (TCAYRCTT) and motif 3 ((T/A)GRTTTCA(G/C)TTT), which were shown to also be important for initiation of transcription by virus. NDV-stimulated nuclear extracts were tested for trans-activating factors able to bind the VRE. The chromosomal protein HMG-I(C) was shown to bind the 3'-A·T-rich domains of the VRE, and the presence of HMG-I(C) was demonstrated in the VRE-protein complex formed with nuclear extracts from NDV-stimulated, but not unstimulated cells. These findings demonstrate the role of HMG-I(C) in activation of MuRantes promoter by NDV.


INTRODUCTION

In order to understand the early host responses to infection, much effort has been focused on the transcriptional activation of inducible genes by viruses. DNA viruses such as adenovirus and herpesviruses encode regulatory proteins that affect the activities of cellular transcription factors. These factors play a role in regulating cell growth and neoplastic transformation through activation of inducible genes (1, 2, 3, 4, 5). Retroviruses are known to affect activation of cellular genes in part through regulating enhancer activities (6). The Paramyxoviridae, a family of negative sense RNA viruses, are potent activators of inducible genes, in particular cytokines (7, 8, 9, 10). This family includes measles virus, canine distemper virus, Sendai virus, and Newcastle disease virus (NDV),1 all of which are neurotropic (11, 12).

Regarding transcriptional activation of cellular genes by Paramyxoviruses, a large body of work has centered on elucidating the mechanisms of IFN-beta gene induction. In addition to NF-kappa B, interferon regulatory factor 1, c-Jun, and ATF-2 (activating transcription factor 2), a DNA-binding protein HMG-I(Y) is required for IFN-beta gene induction by Sendai virus (10, 13). HMG-I(Y) is a member of the high mobility group (HMG) family of chromosomal, non-histone proteins (for review, see Refs. 14 and 15). HMG-I(Y) binds to A·T-rich regions of double-stranded DNA and increases the binding affinity of NF-kappa B and ATF-2 for their respective sites. HMG-I(Y) also induces DNA bending, presumably allowing interactions among multiple transcriptional activators bound at distant sites on the promoter (10).

It has been noted that Paramyxoviruses and bacterial LPS stimulate overlapping, but distinct, sets of cytokine genes (8, 11, 16, 17, 18, 19, 20, 21). In order to determine the similarities and differences between antiviral and antibacterial host response mechanisms at a molecular level, we have examined the inducibility of the murine homolog of RANTES (MuRantes), a member of beta  or C-C chemokine superfamily, in murine macrophages upon stimulation by NDV as compared with LPS. Involvement of RANTES in inflammation through its chemotactic activity for monocytes and eosinophils has been well documented (22, 23, 24). In addition, RANTES is chemotactic for memory T lymphocytes (22). RANTES gene is expressed in a number of cell types including fibroblasts (25), T-cell lines (26), endothelial cells (27), macrophages and macrophage-like cell lines (28), mesangial cells (29), and brain astrocytes and microglia (30).

We have found that the NDV virus-responsive element (VRE) is defined by sequences spanning from nt -175 to -116, which includes the entire region responding to LPS (LRE) (-175/-125), with an additional A·T-rich domain in the 3' border (28). This VRE contains 2 DNA motifs, TCAYRCTT and (T/A)GRTTTCA(G/C)TTT, previously shown to be important for the LRE activity of MuRantes and IP-10/crg-2 chemokine genes (28). Examination of nuclear factors binding to the VRE showed the presence of chromosomal protein HMG-I(C) in NDV-stimulated cells. Although purified HMG-I(C) binds to multiple A·T-rich sequences at the 3' border of MuRantes VRE, not all of them were required for transcription.


EXPERIMENTAL PROCEDURES

Reagents

All reagents were obtained from Sigma unless specifically noted otherwise.

Cell Cultures

The murine macrophage cell line RAW 264.7 was obtained from American Tissue Type Culture (ATCC, Rockville, MD) and maintained in RPMI 1640 (Life Technologies, Inc.) containing 10% fetal bovine serum (FBS; 10% RPMI), L-glutamine, 100 units/ml penicillin/streptomycin, and 25 mM HEPES. Primary macrophages were obtained from peritoneal exudates of 7-week-old C3HeB/FeJ and C3H/HeJ mice (Jackson Laboratories, Bar Harbor, ME) after intraperitoneal injection with 3 ml of a 3% starch solution, as described previously (31).

Viral Stimulation

Cultures were stimulated with various doses of New Jersey La Sota strain of NDV (ATCC). Virus was harvested from 9-day-old, fertilized chick eggs as described previously (32). Mock NDV was from chick amniotic sac aspirates of sham-infected eggs. The viral titer was determined as described in detail elsewhere (32). The infectivity (m.o.i.) was determined in L-cell cytotoxic assay, and the doses used for RAW 264.7 cells were indicated as m.o.i. equivalent to that of L-cell assay. The viral genome was cross-linked under sterile conditions by irradiating virus stock in a 10-cm Petri dish with 300 ergs/cm2 of shortwave ultraviolet (UV) light for 8-10 min. For stimulation, cells were infected with NDV in serum-free RPMI 1640 with gentle rocking every 20 min for 2 h, then an equal volume of RPMI containing 10% FBS was added. Cycloheximide (CHX) and polymyxin B (PB), used at a final concentration of 10 µg/ml, were added with the virus. The tyrosine kinase inhibitor herbimycin A (Life Technologies, Inc.) was added to cells 14 h prior to infection. The protein kinase C inhibitor H7 and its isomer HA1004 (Seikagaku America Corp., Rockville, MD) were added to cells 30 min prior to infection.

Northern Analysis

Total RNA, isolated using RNAzol B (Tel-Test, Inc., Friendswood, TX), was fractionated on a 1% agarose/formaldehyde gel (10 µg of RNA/lane), followed by transfer onto a nitrocellulose membrane (Millipore) with a Posiblot system (Stratagene). The RNA was cross-linked to the membrane with a Stratalinker (Stratagene) and was subsequently probed with a 0.5-kilobase EcoRI, XhoI fragment of MuRantes cDNA and a 1.4-kilobase EcoRI fragment of aldolase A cDNA (a gift of D. Nathans, Johns Hopkins University). The relative amounts of mRNA were quantified on a Computing Densitometer (Molecular Dynamics, Sunnyvale, CA), the integrated volumes were calculated using Imagequant software (Molecular Dynamics), then the density ratio of MuRantes to aldolase A mRNA was obtained.

Plasmids and Mutants

The pG CATm expression vectors carrying MuRantes cDNA spanning -2100/+8, its 5' and 3' deletions, or mutated nucleotides have been prepared previously (28), as described in detail (28, 33). Additional constructs consist of MuRantes promoter containing mutation 11 or 12. As described in Ref. 28, the mutated sequences were generated by polymerase chain reaction-directed mutagenesis in which the 5' primer from -185 was flanked by an SalI site and the 3' primer contained the sequence to +8 and was flanked by an ApaI site. These fragments were then cloned into the pG CATm expression vector.

Transfection and CAT Assay

Transfection using a modified DEAE-dextran method (35) was identical as reported previously (28), except that the transfected cells were infected with NDV. In brief, RAW 264.7 cells transfected with various plasmid constructs were incubated in 10% RPMI for 27 h. After the medium was replaced with serum-free RPMI, cells were scraped, divided into three culture dishes, and incubated for additional 1 h. Each plate was incubated with medium alone, 1 m.o.i. of NDV, or 100 ng/ml LPS. The doses of NDV and LPS were chosen to give comparable CAT activity. Dishes were rocked every 20 min for 2 h. After adding 4.5 ml of 10% RPMI, cells were incubated for 10 h at 37 °C before lysing for CAT assay. Efficiency of transfection was standardized to constitutive levels of beta -galactosidase activity which is not affected by stimulation (28). Cell lysates were assessed for CAT activity according to described methods (36), with minor modifications as used previously (28).

Electrophoretic Mobility Shift Assay (EMSA)

Cell monolayer was stimulated with NDV in the presence of 10 µg/ml CHX in serum-free RPMI for 2 h. After washing with phosphate-buffered saline, pelleted cells were suspended in an equal volume of buffer A: 10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol (DTT), then lysed by repeated aspiration through a 25-gauge needle until over 90% were lysed. Nuclei were stirred for 30 min at 4 °C in extraction buffer (20 mM HEPES, pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM DTT), then centrifuged at 14,000 rpm at 4 °C in an Eppendorf Microfuge. The supernatants were dialyzed for 2 h in 20 mM HEPES, pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM DTT. Protein concentrations were determined by the BCA method (Pierce).

For EMSA, 2-3 µl of nuclear extracts containing 5 µg of protein were mixed with 1 µg of bovine serum albumin and 2 µg of poly(dI:dC)(dI:dC) or poly(dG:dC)(dG:dC) (Pharmacia Biotech Inc.) in a final 20-µl volume by adding 10 mM HEPES, pH 7.9, 16% glycerol, 20 mM NaCl, 4 mM MgCl2, 55 mM KCl, 0.1 mM EDTA, 2 mM DTT, and 2 mM spermidine (28). After incubation at room temperature for 10 min, 0.5 to 5 ng of 32P-probe was added, and the mixtures were incubated for 15 min at 37 °C. After addition of 1 µl of 10 × TBE (0.9 M Tris borate, 20 mM EDTA), samples were separated on a 6% native polyacrylamide gel (28).

DNA Probes

MuRantes probes (-185/-116 and -215/-116) were generated by polymerase chain reaction using 5' primers including a flanking SalI site and 3' primers with BamHI site. Oligonucleotides were appropriately digested for 1 h at 37 °C and labeled by filling in with [32P]dCTP and [32P]dGTP as described previously (28). The NF-kappa B probe is HIV-long terminal repeat, TCAA GCTGCTCTCCTT.

Antibodies

The antibodies to JunD, CREB, c-Fos, p50, and p65 were from Santa Cruz Biotechnology (Santa Cruz, CA). The c-Jun and JunB antibodies were obtained from Oncogene Science (Uniondale, NY). Anti-HMG-I(C) IgG was a gift from J. Maher.


RESULTS

NDV Induced MuRantes mRNA Accumulation in RAW 264.7 Cells

The kinetics of NDV-induced MuRantes gene expression and the dose of NDV required were examined in RAW 264.7 cells by Northern analysis (Fig. 1). MuRantes transcripts were detected at 4 h, reached the maximum between 8 and 24 h (Fig. 1A), then markedly reduced at 48 h (data not shown). At 6 h of stimulation, MuRantes mRNA expression was increased with increasing m.o.i. of NDV (Fig. 1B). MuRantes mRNA was induced by live virus, but not by mock NDV or NDV-depleted supernatants (Fig. 2). Induction also occurred when cells were stimulated by NDV in the presence of cycloheximide (CHX) or polymyxin B (PB), indicating that MuRantes gene induction by NDV occurred in an immediate early manner, as has been shown for LPS stimulation (28), and was not due to contaminating LPS. UV-irradiated virus (UV-NDV) also induced MuRantes. Induction of MuRantes gene by NDV does not require viral replication, since UV and CHX treatments render the NDV unable to replicate, a finding also seen in induction of complement C3 and IP-10/crg-2 genes by UV-NDV (37, 38).


Fig. 1. Induction of MuRantes mRNA expression in RAW 264.7 cells stimulated with NDV. A, cells in monolayer were stimulated with 3 m.o.i. of NDV for 2 h in serum-free medium, then in RPMI/5% FBS for the indicated periods. Total cellular RNA was isolated, and MuRantes mRNA was measured by Northern blot (10 µg of RNA/lane). Aldolase A was used as a control to normalize MuRantes mRNA in each lane. The mRNA density of the autoradiogram was analyzed by two-dimensional densitometric quantitation, and results are shown as mRNA density ratios of MuRantes/aldolase. B, RAW 264.7 cells were stimulated with increasing doses of NDV for 6 h, then the mRNA expression was determined by Northern blot (10 µg of RNA/lane). Results are shown as mRNA density ratios of MuRantes/aldolase.


Fig. 2. Induction of MuRantes mRNA by NDV and UV-NDV. A, RAW 264.7 cells were stimulated with 3 m.o.i. NDV for 2 h in serum-free medium, then in RPMI/5% FBS for 4 h. Northern blot analysis was used to assess MuRantes mRNA induction in cells stimulated with mock-infected amniotic sac aspirates (mock NDV), NDV-depleted supernatants (NDV-supe), UV-irradiated NDV (UV-NDV), UV-NDV plus 10 µg/ml polymyxin B (+PB), NDV, NDV plus polymyxin B (NDV+PB), PB alone, NDV plus 10 µg/ml cycloheximide (+CHX), or CHX alone. B, the autoradiographic bands were quantitated and results are expressed as mRNA density ratios of MuRantes/aldolase.

Induction of MuRantes mRNA Expression in Peritoneal Macrophages

To examine possible differences between NDV and LPS as stimuli, macrophages were obtained from LPS-responsive strain C3HeB/FeJ mice and C3H/HeJ mice which carry a mutation of the lps gene rendering them hyporesponsive to LPS (39). NDV-induced MuRantes mRNA accumulation in both strains of mice, C3HeB/FeJ and C3H/HeJ, while LPS failed to elicit any induction in C3H/HeJ, as expected (Fig. 3). In the presence of CHX, NDV superinduced MuRantes in macrophages of both strains, as in primary rat astrocytes (30), but not in RAW 264.7 cell line (28). Since NDV induced MuRantes mRNA in LPS-hyporesponsive macrophages, the pathways of transcriptional activation by LPS and NDV cannot be identical. Studies to evaluate this issue by examining signal pathways using inhibitors are shown in Fig. 4. Tyrosine kinase inhibitor herbimycin A had a potent inhibitory effect on the NDV-mediated mRNA expression, whereas the LPS-induced expression was much less sensitive (Fig. 4A). The potent protein kinase C inhibitor H7 (40) blocked the induction by both stimuli at the same concentration (Fig. 4B). HA1004, an H7 isomer which strongly inhibits cyclic nucleotide-dependent kinases (40), markedly inhibited the LPS-induced induction, but was minimally effective for NDV (Fig. 4C). These data indicate involvement of distinct multiple effector pathways in inducing MuRantes gene. The inhibitors were not cytotoxic, as determined by the level of lactate dehydrogenase in supernatants, which is released upon cell death (data not shown).


Fig. 3. Induction of MuRantes mRNA in peritoneal macrophages from LPS-responder C3HeB/FeJ and LPS hyporesponder C3H/HeJ mice. Starch-elicited peritoneal macrophages from C3HeB/FeJ (upper panel) or C3H/HeJ (lower panel) mice were stimulated for 4 h with 3 m.o.i. NDV or 300 ng/ml LPS in the presence or absence of 10 µg/ml CHX. MuRantes mRNA accumulation was determined by Northern analysis (10 µg of RNA/lane). Aldolase mRNA was used as a control.


Fig. 4. Effects of inhibitors of signal pathways on LPS- and NDV-induced MuRantes mRNA. A, effects of herbimycin A. RAW 264.7 cells pretreated with 0.5 to 1 µM herbimycin A or with medium for 18 h were stimulated with 3 m.o.i. NDV or 300 ng/ml LPS for 6 h. MuRantes mRNA expression was then detected by Northern blot analysis (10 µg of RNA/lane). Cells treated with herbimycin alone were also included. B, effects of H7. RAW 264.7 cells pretreated with 1 to 60 µM H7 for 30 min were stimulated with 3 m.o.i. NDV or 300 ng/ml LPS for 6 h. MuRantes mRNA expression was determined as in A. C, effects of HA1004. RAW 264.7 cells pretreated with 30 or 60 µM HA1004 for 30 min were then stimulated with 3 m.o.i. NDV or 300 ng/ml LPS as above.

Stimulation of MuRantes Promoter Activity by NDV

After establishing MuRantes gene induction by NDV, the nucleotide sequences of the 5'-regulatory region of MuRantes gene required for the NDV-VRE were analyzed by CAT assay in RAW 264.7 cells. Cells transfected with pG CATm carrying cDNA spanning nt -2100 to +8 showed significant CAT activity upon NDV stimulation compared to unstimulated or mock NDV-stimulated cells (Fig. 5). The presence of FBS enhanced the efficiency of induction by LPS and NDV. The results of deletion analysis to determine the 5' and 3' boundaries required for viral inducibility, are presented in Fig. 6, A and B, as a histogram. Deletion from nt -2100 to -215 relative to the transcriptional start site had virtually no effect on virus-induced CAT activity (Fig. 6A). Full activity was maintained until a deletion of 3 nt from -175 to -172, which reduced the relative CAT activity to 37.3% ± 8.2. A further deletion from nt -167 to -155 completely abolished the activity. The 3' boundary was delineated using 3' deletion constructs containing heterologous hamster sarcoma virus-thymidine kinase minimal promoter (34). When the promoter activity of nt -185 to -116 was considered as 100%, deletion to nt -125 reduced the activity to 52.3% ± 17.5 and deletion to nt -138 completely abolished the activity (Fig. 6B). The activity of a longer nt -185 to -60 segment was consistently lower (52.1% ± 10.3), suggesting a repressor site within nt -116 and -60 (see Fig. 7B). Therefore, MuRantes VRE lies between nt -175 and -116 and contains a 6/7 AP-1 site, a 8/10 NF-kappa B site, and a 9/12 ISRE site (nt -114 to -156) (Fig. 7). MuRantes induction is unlikely to occur through the ISRE core since this promoter is not inducible by IFNs (28). Cells were stimulated by LPS and NDV side by side, whereby the previously described 5' and 3' boundaries of LRE (-175/-125) (28) have been verified in this study (data not shown). The pattern of relative CAT activity induced in these constructs by LPS and NDV show marked similarities. Therefore, the 5' boundary of the VRE (-175) was closely aligned to that of the LRE and the 3' boundary of VRE (-116) was found to extend further than the LRE.


Fig. 5. Induction of CAT activity by NDV in RAW 264.7 cells transiently transfected with MuRantes promoter-CAT constructs. A, the 5'-flanking region of the MuRantes gene spanning -2100 to +8 which includes the MuRantes minimal promoter (28) was ligated upstream of the CAT coding region in the pG CATm plasmid. B, this construct was transiently transfected into RAW 264.7 cells as described under ``Experimental Procedures.'' Cells were then stimulated with 30 m.o.i. NDV, mock NDV, or 300 ng/ml LPS in serum-free medium for 2 h. One set of cultures had RPMI/10% FBS added after 2 h, for the remaining 10 h (+FBS). The CAT activity was determined as described under ``Experimental Procedures.'' C, relative CAT activity of each assay was determined by correcting the value for cell number by standardizing for beta -galactosidase activity and subtraction of the values of the unstimulated cells. The CAT activity in cells stimulated with NDV + FBS was considered as 100%.


Fig. 6. CAT activity of 5'- and 3'-deletion constructs of MuRantes promoter stimulated with NDV. A, RAW 264.7 cells transfected with MuRantes promoter-CAT constructs carrying 5'-nested deletions were stimulated with 1 m.o.i. NDV for 12 h. CAT assay was performed with cell lysates as described. Relative CAT activities ± S.E. in NDV-stimulated cells from 3 separate experiments are shown. The CAT activity of -215/+8 construct was considered as 100%. B, the 3'-nested deletion constructs of MuRantes promoter were prepared by using a 3' polymerase chain reaction primer with the appropriate sequence flanked by a site which was generated by polymerase chain reaction and then inserted into the pBL CAT2 vector which contains a heterologous thymidine kinase minimal promoter upstream of the CAT coding region. RAW 264.7 cells transfected with MuRantes promoter-CAT constructs were stimulated with 1 m.o.i. NDV, as in A. Relative CAT activities ± S.E. in response to NDV from 4 separate experiments are shown. The CAT activity of -185/-116 construct was taken as 100%.


Fig. 7. The 5' and 3' borders of MuRantes VRE. A, using data shown in Fig. 6, the 5' and 3' borders of the VRE of the MuRantes promoter are depicted (hatched bar). Two nucleotide sequences, motif 1 and motif 3, shared with the LRE of MuRantes and murine IP-10/crg-2 promoters (28) are underlined with a bold bar. The AP-1 and NF-kappa B binding sites are indicated, along with the number of consensus nucleotides. B, nucleotide sequence of the 220-bp 5'-flanking region and the 59-bp 5'-untranslated region is shown. Binding sites for EBP-1, AP-1, NF-kappa B, and AP-2 are underlined. The CAT and TATA boxes are also shown (boxed).

Mutational Analysis of the MuRantes VRE

Both the VRE and LRE contain 2 conserved sequences shared with muIP-10/crg-2 LRE (28): motif 1, TCAYRCTT, and motif 3, (T/A)GRTTTCA(G/C)TTT (Fig. 7). Since the VRE also contains an AP-1 site (6/7) and an NF-kappa B-like site (8/10), possible utilization of these sites for transcription was examined by mutational analysis. Results from 4 separate experiments revealed two regions critical for NDV inducibility (Fig. 8). A half AP-1 site (TCA) in motif 1 is flanked on the 3' side by 5 nt, and on the 5' side by the other half of the AP-1 site (Fig. 8A). The first required domain was identified by mutations 1 through 4 (M1-M4). Mutation 1 (M1) in the 5'-half AP-1 site resulted in a moderate loss of activity (37.3% ± 7.3 in relation to nt -185 to +8 wild type construct). M3 which involves the 3'-half of the AP-1 site and the 5'-half of motif 1 caused dramatic loss of activity. M2, which altered both 5'- and 3'-halves of the AP-1 site as well as motif 1, had an even more profound loss of activity. M4, which changed 3 bases flanking the half AP-1 site in motif 1, reduced the activity to 48.4% ± 4.1. M5 and M6 carrying mutated bases of motif 2 between motif 1 and motif 3, did not influence the CAT activity. A second critical region was identified through the use of M8 through M12 constructs. M8 decreased the VRE activity close to 60%. M9 and M10, which affect A·T-rich domains within motif 3, totally abolished the VRE activity. It was significant that M10 which lies within motif 3, but outside of the NF-kappa B-like site, as well as M11 abolished the promoter activity (0.3% ± 0.3). M12 showed significant VRE activity upon NDV stimulation (57%). In addition, M7, which alters the highly conserved nucleotides of the potential NF-kappa B site, had no effect on virus inducibility. These functional data indicate that in addition to motif-1, three A·T-rich domains, two of them located within motif 3, are required for the VRE activity. The data also imply that the NF-kappa B like site within the VRE is unlikely to participate in NDV induction of MuRantes, as was previously found for LPS (28), even though both LPS and NDV can induce NF-kappa B DNA binding activity (data not shown), as reported by others (6, 41, 42). The CAT activity induced by LPS determined along with the virus using M1-M10 constructs, which was closely similar to the previously published values (28), also showed a similarity to the activity induced by NDV, except that mutation M9 produced partial reduction in LPS-treated cells, but a near-complete loss in NDV-infected cells. NDV and LPS also produced similar results for M11 and M12.


Fig. 8. Delineation of the VRE by mutational analysis of MuRantes promoter. A, wild type sequences were mutated 3, 4, or 7 bases at a time, as boxed, and the mutations are indicated as M1 through M12. Motif-1, motif-3, the AP-1 site (6/7), and a NF-kappa B-like site (8/10) are also indicated. B, after transient transfection with MuRantes-CAT constructs containing each mutation, RAW 264.7 cells were stimulated with 1 m.o.i. NDV. The relative CAT activities ± S.E. from 5 separate experiments are shown. The activity of wt -185/+8 construct was considered as 100%.

Examination of the DNA-binding Factors Involved in MuRantes Induction

The properties of the DNA-binding factors were examined by EMSA using poly(dG:dC)(dG:dC) and poly(dI:dC)(dI:dC) as nonspecific competitors (Fig. 9A). With poly(dI:dC)(dI:dC), formation of VRE-protein complexes in unstimulated or stimulated nuclear extracts was markedly reduced when compared to those formed with poly(dG:dC)(dG:dC). Using poly(dG:dC)(dG:dC), a single slower mobility band in unstimulated extracts and two closely spaced faster mobility bands in NDV-stimulated extracts were observed, all of which were competed away with 20-fold excess of cold wt VRE (nt -185 to -116) (Fig. 9, A and B). As shown in Fig. 9, A and B, unstimulated nuclear extracts formed a single band of slower mobility that can be competed away with wt VRE. The nature of this band is currently unknown. As shown in Fig. 9B, VRE complexes formed with NDV-stimulated extracts that can be competed away with wt VRE (lanes 3 and 4), were not competed with a wt- or mutation 6-containing 30-mer (-167/-137) (lanes 5 and 6). However, full-length VRE (-185/-116) with M7, M10, and M12 were effective as competitive inhibitors (lanes 7, 8, and 10). M11 VRE partially inhibited the complex formation (lane 9). A significant finding is that M7 (mutation of the NF-kappa B-like site) inhibited the complex formation with similar efficiency as wt VRE. The inability of truncated wt 30-mer sequences to inhibit the VRE-complex formation was correlated with the failure of a wt 30-mer (-167/-137), used as a probe, to form DNA-protein complexes (Fig. 9C). These results collectively indicate that both motif 1 and motif 3 plus A·T-rich sequences may be required to form VRE-protein complexes in NDV-stimulated nuclear extracts. The finding that complex formation was inhibited by M10, M11, and M12 VRE, each containing mutations affecting a single A·T-rich domain, suggested a cooperative binding to the A·T-rich domains. We have not tested VRE in which all of A·T-rich domains are mutated.


Fig. 9. Formation of the VRE-protein complexes. A, nuclear extracts (5 µg of protein) from unstimulated or NDV-stimulated (2 h, 3 m.o.i.) RAW 264.7 cells were mixed with nonspecific competitor poly(dI:dC)(dI:dC) or poly(dG:dC)(dG:dC) prior to the addition of labeled MuRantes VRE (-185/-116) with (+) or without (-) 20-fold excess of cold competitor, -185/-116, as described in detail under ``Experimental Procedures.'' The VRE complexes were detected by EMSA on 6% nondenaturing acrylamide gel. B, VRE complexes formed with unstimulated or NDV-stimulated (2 h, 3 m.o.i.) nuclear extracts were examined in the presence of 20-fold excess of various unlabeled DNA sequences. Unstimulated nuclear extracts forming a single band of slower mobility are shown (lanes 1 and 2). VRE complexes formed with NDV-stimulated extracts (lane 3) and competed with wt VRE -185/-116 and a 30-mer -167/-137 of wt and mutation 6 (M6) are shown in lanes 4-6. Competitive inhibition with VRE -185/-116 with M7, M10, M11, and M12 are shown in lanes 7-10. VRE probe (-185/-116) is shown in lane 11. C, NDV-stimulated nuclear extracts were incubated with labeled 30-mer -167/-137, and DNA-protein complex formation was examined by EMSA as above.

Presence of HMG-I(C) in NDV-stimulated Nuclear Extract and Binding of HMG-I(C) to MuRantes VRE

Since formation of the VRE-protein complex was inhibited by poly(dI:dC)(dI:dC) which appears similar to A·T-rich DNA with respect to hydrogen bond formation in the minor groove, and since MuRantes VRE also contains A·T-rich regions in the 3' border, a possible role for the HMG-I family of proteins was explored. The presence of HMG-I(C) in VRE-protein complexes was detected by anti-HMG-I(C) antibody, which supershifted the complexes formed with NDV-stimulated nuclear extracts (Fig. 10A, lanes 9-12), but not with unstimulated extracts (lanes 5-8). Purified HMG-I(C), 10 nM, formed two bands with wt VRE probe, and the complexes were also supershifted with antibody (lanes 1-4). In EMSA, purified HMG-I(C) formed a single mobility complex with a wt 30-mer (-167/-137) (Fig. 10B), and the HMG-I(C) binding to this 30-mer probe was markedly diminished when any one of the 2 A·T-rich domains was mutated (M10, M11). The binding of HMG-I(C) to a 30-mer (-161/-131) which contains M12 was also significantly decreased. Although each of these A·T rich domains is the target for HMG-I(C) binding, the role of M12 site in transcriptional activity of the VRE may not be as important as the A·T-rich sites effected by M9, M10, and M11, based on the results of the CAT assay. The supershift with anti-HMG-I(C) carried out with LPS-stimulated nuclear extracts was far below the level achieved with virus-stimulated nuclear extracts (data not shown).


Fig. 10. The VRE-protein complexes formed with NDV-stimulated nuclear extracts contain HMG-I(C). A, labeled wt VRE -185/-116 and unstimulated (lanes 5-8) or NDV-stimulated nuclear extracts (lanes 9-12) were incubated with anti-HMG-I(C) IgG at 1/2.5 and 1/5 dilutions as described under ``Experimental Procedures.'' Supershifted complexes were detected by EMSA. The binding of purified HMG-I(C), 10 nM, to wt VRE probe (-185/-116) was examined by EMSA using anti-HMG-I(C) (lanes 1-4). B, purified HMG-I(C) binding to the A·T-rich sequences of the VRE was evaluated using wt 30-mer (-167/-137), a 30-mer (-167/-137) with mutated A·T-rich sequences, M10, or M11, and a 30-mer (-161/-131) with M12.

Studies of AP-1-binding Factors and NF-kappa B in VRE-Protein Complexes

Proteins capable of binding to NF-kappa B and AP-1 sites were examined using antibodies (Fig. 11). Only anti-c-Jun supershifted the VRE-protein complex (lane 11). Although the effect was detected only in overexposed autoradiograms, this finding was consistently reproduced in 4 separate experiments. Antibodies to c-Fos, JunB, JunD, CREB, p50, and p65 were unable to supershift the VRE-protein complexes. NF-kappa B binding to the HIV-long terminal repeat NF-kappa B probe was induced in NDV- or LPS-stimulated nuclear extracts, and the binding was not competed away with wt VRE or M7 VRE (data not shown).


Fig. 11. Identification of proteins in the VRE-protein complexes using antibodies to AP-1 proteins, NF-kappa B, and HMG-I(C). Unstimulated (lanes 1-9) and NDV-stimulated (lanes 10-18) nuclear extracts (5 µg) were allowed to bind to labeled VRE -185/-116. Samples were then incubated with antibodies for 1 h at 4 °C, and evidence of supershifting bands was assessed by EMSA. This blot was overexposed to detect any bands supershifted by antibodies. Clearly supershifted complexes are observed with NDV-stimulated samples treated with anti-c-Jun (lane 11) and anti-HMG-I(C) (lane 18). Antibodies including anti-JunB, anti-JunD, anti-CREB, anti-c-Fos, anti-p50, and anti-p65, supplied as IgG were used at 2 µg in the binding assay.


DISCUSSION

In this study, we have shown that the murine RANTES (MuRantes) chemokine gene is induced by NDV in an immediate early manner in RAW 264.7 cells. MuRantes mRNA induction does not require the synthesis of viral proteins or double-stranded viral RNA since CHX + NDV and UV-NDV showed induction efficiency similar to live virus. These results were reproduced in primary peritoneal macrophages elicited with starch from C3HeB/FeJ mice. However, MuRantes gene was induced by NDV, but not by LPS in macrophages from C3H/HeJ mice, an LPS-hyporesponsive strain. In addition, MuRantes mRNA expression induced by NDV and LPS showed stimulus-specific susceptibility to signal pathway inhibitors. Herbimycin, a tyrosine kinase inhibitor, preferentially inhibited NDV-stimulated mRNA accumulation, whereas HA1004, a cyclic nucleotide-dependent kinase inhibitor, was more effective in inhibiting the LPS effect. These results indicate that induction of MuRantes gene by NDV and LPS is through distinctly different pathways. In this context, it is interesting that the VRE and LRE of the MuRantes promoter shared extensive sequence homology: the minimal VRE lies between nt -175 and -116 and the LRE between nt -175 and -125. The VRE also shared with LRE certain DNA motifs, designated motif 1 and motif 3, which were required for MuRantes transcription, as shown by mutational analysis. Motif 3 contains two A·T-rich domains, each of which when mutated as M9 or M10 abolished the VRE activity. In contrast, mutation of the first A·T-rich domain (M9) reduced the LRE activity only partially (28). The VRE carries additional A·T-rich sequence repeats in the 3' border, to which HMG-I(C) was shown to bind. It is likely that virus and LPS may use overlapping, but not identical, sets of transcription factors that interact with multiple sites within the VRE and LRE. However, it remains to be determined whether VRE and LRE associate with distinct proteins regulated through different signaling pathways.

We have noted that poly(dI:dC)(dI:dC) decreased VRE-protein complex formation, while the LRE-protein complexes were less affected (data not shown). This inhibitory effect of poly(dI:dC)(dI:dC) may be due to its structural similarity to the minor groove of double-stranded, A·T-rich DNA sequences, thereby allowing it to compete with minor groove binding proteins like HMG-I (43, 44, 45). Earlier studies have demonstrated that HMG-I(Y) participates in transcription of IFN-beta gene induced by Sendai virus by enhancing the affinity of NF-kappa B and ATF-2 to their respective binding sites (10, 13). We have demonstrated that HMG-I(C), a member of the HMG-I family of proteins (46, 47), was present in the VRE-protein complex formed with NDV-stimulated nuclear extracts, but not the VRE complex of unstimulated extracts. These data indicated that NDV-induced post-transcriptional activation of HMG-I(C) allows the assembly of the VRE-protein complex needed for transcription rather than induction of HMG-I(C) synthesis, since MuRantes gene induction by NDV was not affected by CHX. The presence of multiple HMG-I(C) binding sites and the failure of VRE containing M9, M10, or M11 to induce transcription suggest possible cooperative activity among HMG-I(C) proteins and between HMG-I(C) and other DNA-binding factors. LPS-induced CAT activity was only partially affected by M9 and the potency of anti-HMG-I(C) to supershift the LRE-protein complexes was reduced significantly compared with that of virus. Thus, the possible effects of HMG-I(C) on MuRantes transcription in response to virus and LPS may be quantitative.

It was unexpected that the 8/10 NF-kappa B binding site failed to play a major role in virus-mediated activation of this protein. It is possible that the binding site sequences are not favorable for NF-kappa B binding. Activated NF-kappa B may still play a role through binding to transcription factors such as c-Jun (48). As shown here, it is likely that c-Jun in the VRE-protein complexes may interact with motif 1 and the 5'-flanking half AP-1 site. The interaction among DNA-binding proteins may be regulated by HMG-I(C) in the VRE and the binding specificities, and possible partners that may dimerize with c-Jun in the VRE and LRE may not be identical. Various trans-activating proteins, through homo- or heterodimer formation, are known to generate response diversity by affecting binding affinity and/or selecting different flanking sequences for binding (for review, see Ref. 49). The A·T-rich sequences in the VRE that can bind multiple HMG-I(C) may also play a critical regulatory role in generating additional diversity by enhancing the binding of specific transcription factors and by allowing protein-protein interaction through DNA bending.

It would be surprising if the molecular mechanisms used to induce common cytokines by bacterial and viral pathogens evolved as totally separate pathways. Therefore, the extensively overlapping sequence motifs between the LRE and VRE in MuRantes induction are not unexpected. These findings also indicate that host defense mechanisms to viral and bacterial infection may be achieved by utilizing similar or closely overlapping molecular events.


FOOTNOTES

*   This work was supported by Grants RO1 CA1411320, RO1 AI19622, RO1 NS 15662, and NS 20022 from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   Present address: Dept. of Medical Microbiology and Immunology, University of Wisconsin School of Medicine, Madison, WI 53706.
par    Present address: Dept. of Medicine, University of Mississippi, School of Medicine, Jackson, MS 39216.
''   To whom correspondence and reprint requests should be addressed: Dept. of Pathology, University of Maryland School of Medicine, 10 South Pine St., Baltimore, MD 21201. Tel.: 410-706-7892; Fax: 410-706-7706.
'''   Present address: Samsung Biomedical Research Institute, 50 Ilwon-Dong, Seoul, Korea 135-230.
1   The abbreviations used are: NDV, Newcastle disease virus; LPS, lipopolysaccharide; LRE, LPS-responsive element; VRE, virus-responsive element; nt, nucleotide(s); IFN, interferon; HMG, high mobility group; NF, nuclear factor; IP-10, inflammatory protein, 10 kDa; crg, cytokine-responsive gene; AP-1, activator protein 1; CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility shift assay; m.o.i., multiplicity of infection; FBS, fetal bovine serum; CHX, cycloheximide; PB, polymyxin B; UV-NDV, ultraviolet-irradiated NDV; DTT, dithiothreitol; wt, wild type; ISRE, interferon stimulus response element.

Acknowledgments

We express sincere appreciation to Dr. Daniel Nathans for critically reviewing the experimental data and the manuscript. We thank William Paznekas and Chun-Min Chi for their valuable technical assistance.


REFERENCES

  1. Abdel-Hafiz, H. A.-M., Chen, C. Y., Marcell, T., Kroll, D. J., Hoeffler, J. P. (1993) Oncogene 8, 1161-1174 [Medline] [Order article via Infotrieve]
  2. van Dam, H., Duyndam, M., Rottier, R., Bosch, A., de Vries-Smits, L., Herrlich, P., Zantema, A., Angel, P., van der Eb, A. J. (1993) EMBO J. 12, 479-487 [Medline] [Order article via Infotrieve]
  3. Liu, F., Green, M. R. (1990) Cell 61, 1217-1224 [CrossRef][Medline] [Order article via Infotrieve]
  4. Chatton, B., Bocco, J. L., Gaire, M., Hauss, C., Reimund, B., Goetz, J., Kedinger, C. (1993) Mol. Cell. Biol. 13, 561-570 [Abstract/Free Full Text]
  5. Chellappan, S. P., Hiebert, S., Mudryj, M., Horowitz, J. M., Nevins, J. R. (1991) Cell 65, 1053-1061 [CrossRef][Medline] [Order article via Infotrieve]
  6. Roulston, A., Beauparlant, P., Rice, N., Hiscott, J. (1993) J. Virol. 67, 5235-5246 [Abstract/Free Full Text]
  7. Taniguchi, T. (1988) Annu. Rev. Immunol. 6, 439-464 [CrossRef][Medline] [Order article via Infotrieve]
  8. Au, W.-C., Raj, N. B. K., Pine, R., Pitha, P. M. (1992) Nucleic Acids Res. 20, 2877-2884 [Abstract/Free Full Text]
  9. Tanaka, N., Taniguchi, T. (1992) Adv. Immunol. 52, 263-281 [Medline] [Order article via Infotrieve]
  10. Du, W., Thanos, D., Maniatis, T. (1993) Cell 74, 887-898 [CrossRef][Medline] [Order article via Infotrieve]
  11. Nagai, Y., Hamaguchi, M., Toyoda, T. (1989) Prog. Vet. Microbiol. Immunol. 5, 16-64 [Medline] [Order article via Infotrieve]
  12. Galinsli, M. S., Wechsler, S. L. (1991) The Paramyxoviruses (Kingsbury, D. W., eds) , p. 41, Plenum Press Inc., New York
  13. Thanos, D., Maniatis, T. (1992) Cell 71, 777-789 [CrossRef][Medline] [Order article via Infotrieve]
  14. Einck, L., Bustin, M. (1985) Exp. Cell Res. 156, 295-310 [CrossRef][Medline] [Order article via Infotrieve]
  15. Bustin, M., Lehn, D. A., Landsman, D. (1990) Biochim. Biophys. Acta 1049, 231-243 [Medline] [Order article via Infotrieve]
  16. Lieberman, A. P., Pitha, P. M., Shin, H. S., Shin, M. L. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 6348-6352 [Abstract/Free Full Text]
  17. Ohno, S., Taniguchi, T. (1983) Nucleic Acids Res. 11, 5403-5412 [Abstract/Free Full Text]
  18. Aznar, C., Fitting, C., Cavaillon, J.-M. (1990) Cytokine 2, 259-265 [CrossRef][Medline] [Order article via Infotrieve]
  19. Zawatsky, R., Homfeld, A. (1991) Pathobiology 59, 232-236 [Medline] [Order article via Infotrieve]
  20. Raj, N. B. K., Au, W.-C., Pitha, P. M. (1991) J. Biol. Chem. 266, 11360-11365 [Abstract/Free Full Text]
  21. Fisher, S. N., Kim, Y.-U., Shin, M. L. (1994) J. Immunol. 153, 3210-3217 [Abstract]
  22. Schall, T. J., Bacon, K., Toy, K. J., Goeddel, D. V. (1990) Nature 347, 669-671 [CrossRef][Medline] [Order article via Infotrieve]
  23. Rot, A., Krieger, M., Brunner, T., Bischoff, S. C., Schall, T. J., Dahinden, C. A. (1992) J. Exp. Med. 176, 1489-1495 [Abstract/Free Full Text]
  24. Meurer, R., Van Riper, G., Feeney, W., Cunningham, P., Hore, D., Jr., Springer, M. S., MacIntyre, D. E., Rosen, H. (1993) J. Exp. Med. 178, 1913-1921 [Abstract/Free Full Text]
  25. Rathanaswami, P., Hachicha, M., Sadick, M., Schall, T. J., McColl, S. R. (1993) J. Biol. Chem. 268, 5834-5839 [Abstract/Free Full Text]
  26. Nelson, P. J., Kim, H. T., Manning, W. C., Goralski, T. J., Krensky, A. M. (1993) J. Immunol. 151, 2601-2612 [Abstract]
  27. Marfaing-Koka, A., Odile, D., Gorgone, G., Portier, A., Schall, T. J., Galanaud, P., Emilie, D. (1995) J. Immunol. 154, 1870-1878 [Abstract]
  28. Shin, H. S., Drysdale, B.-E., Shin, M. L., Noble, P. W., Fisher, S. N., Paznekas, W. A. (1994) Mol. Cell. Biol. 14, 2914-2925 [Abstract/Free Full Text]
  29. Wolf, G., Thasis, S. F., Nelson, P. J., Krensky, A. M., Neilson, E. G., Stahl, R. A. K. (1993) Kidney Int. 44, 795-804 [Medline] [Order article via Infotrieve]
  30. Fisher, S. N., Vanguri, P., Shin, H. S., Shin, M. L. (1995) Brain Behav. Immun. 9, 331-344 [CrossRef][Medline] [Order article via Infotrieve]
  31. Drysdale, B. E., Zacharchuk, C. M., Okajima, M., Shin, H. S. (1986) Methods Enzymol. 132, 549-555 [Medline] [Order article via Infotrieve]
  32. Shin, M. L., Lieberman, A. P., and Fisher, S. N. (1993) in Neurobiology of Cytokines (De Souza, E. B., ed) Part B, pp. 16-34, Academic Press, Inc., La Jolla, CA
  33. Vanguri, P., Farber, J. M. (1990) J. Biol. Chem. 265, 15049-15057 [Abstract/Free Full Text]
  34. Luckow, B., Schultz, G. (1987) Nucleic Acids Res. 15, 5490 [Free Full Text]
  35. Sambrook, J., Fritsch, G., Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , p. 16.41, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  36. Gorman, C. M., Moffat, L. F., Howard, B. H. (1982) Mol. Cell. Biol. 2, 1044-1051 [Abstract/Free Full Text]
  37. Rus, H. G., Kim, L. M., Niculescu, F. I., Shin, M. L. (1992) J. Immunol. 148, 928-933 [Abstract]
  38. Vanguri, P., Farber, J. M. (1994) J. Immunol. 152, 1411-1418 [Abstract]
  39. Rosenstreich, D. L. (1985) Cellular Biology of Endotoxin (Berry, L. J., eds) , p. 82, Elsevier Science Publishers B.V., Amsterdam
  40. Hidaka, H., Inagaki, M., Kawamoto, S., Sasaki, Y. (1984) Biochemistry 23, 5036-5041 [CrossRef][Medline] [Order article via Infotrieve]
  41. Liou, H.-C., Baltimore, C. (1993) Curr. Opin. Cell Biol. 5, 477-487 [CrossRef][Medline] [Order article via Infotrieve]
  42. Grilli, M., Chiu, J. J.-S., Lenardo, M. J. (1993) Int. Rev. Cytol. 143, 1-62 [Medline] [Order article via Infotrieve]
  43. Elton, T. S., Nissen, M. S., Reeves, R. (1987) Biochem. Biophys. Res. Commun. 143, 260-265 [CrossRef][Medline] [Order article via Infotrieve]
  44. Starr, D. B., Hawley, D. K. (1991) Cell 67, 1231-1240 [CrossRef][Medline] [Order article via Infotrieve]
  45. Giese, K., Cox, J., Grosschedl, R. (1992) Cell 69, 185-195 [CrossRef][Medline] [Order article via Infotrieve]
  46. Giancotti, V., Bandiera, A., Buratti, E., Fusco, A., Marzari, R., Coles, B., Goodwin, G. H. (1991) Eur. J. Biochem. 198, 211-216 [Medline] [Order article via Infotrieve]
  47. Manfioletti, G., Giancotti, V., Bandiera, A., Buratti, E., Sautiere, P., Cary, P., Crane-Robinson, C., Coles, B., Goodwin, G. H. (1991) Nucleic Acids Res. 19, 6793-6797 [Abstract/Free Full Text]
  48. Stein, B., Baldwin, A. S., Jr., Ballard, D. W., Greene, W. C., Angel, P., Herrlich, P. (1993) EMBO J. 12, 3879-3891 [Medline] [Order article via Infotrieve]
  49. Lamb, P., McKnight, S. L. (1991) Trends Biochem. Sci. 16, 417-422 [CrossRef][Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
J. M. Chen, H. Ren, J. E. Shaw, Y. J. Wang, M. Li, A. S. Leung, V. Tran, N. M. Berbenetz, D. Kocincova, C. M. Yip, et al.
Lsr2 of Mycobacterium tuberculosis is a DNA-bridging protein
Nucleic Acids Res., April 1, 2008; 36(7): 2123 - 2135.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. Melchjorsen, L. N. Sorensen, and S. R. Paludan
Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function
J. Leukoc. Biol., September 1, 2003; 74(3): 331 - 343.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
J. F. Schiltz, K. Kesari, H. R. Ashar, and K. Chada
Hmgi-c-independent Activation of MuRantes in Vivo
Cell Growth Differ., January 1, 2002; 13(1): 39 - 45.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. J. Holtzman, J. D. Morton, L. P. Shornick, J. W. Tyner, M. P. O'Sullivan, A. Antao, M. Lo, M. Castro, and M. J. Walter
Immunity, Inflammation, and Remodeling in the Airway Epithelial Barrier: Epithelial-Viral-Allergic Paradigm
Physiol Rev, January 1, 2002; 82(1): 19 - 46.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
K.-Y. Chau, N. Munshi, A. Keane-Myers, K.-W. Cheung-Chau, A. K.-F. Tai, G. Manfioletti, C. K. Dorey, D. Thanos, D. J. Zack, and S. J. Ono
The Architectural Transcription Factor High Mobility Group I(Y) Participates in Photoreceptor-Specific Gene Expression
J. Neurosci., October 1, 2000; 20(19): 7317 - 7324.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. R. Horton, M. A. Olman, C. Bao, K. E. White, A. M. K. Choi, B.-Y. Chin, P. W. Noble, and C. J. Lowenstein
Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages
Am J Physiol Lung Cell Mol Physiol, October 1, 2000; 279(4): L707 - L715.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Genin, M. Algarte, P. Roof, R. Lin, and J. Hiscott
Regulation of RANTES Chemokine Gene Expression Requires Cooperativity Between NF-{kappa}B and IFN-Regulatory Factor Transcription Factors
J. Immunol., May 15, 2000; 164(10): 5352 - 5361.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. E. Rollo, K. P. Kumar, N. C. Reich, J. Cohen, J. Angel, H. B. Greenberg, R. Sheth, J. Anderson, B. Oh, S. J. Hempson, et al.
The Epithelial Cell Response to Rotavirus Infection
J. Immunol., October 15, 1999; 163(8): 4442 - 4452.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Koga, E. Sardina, R. M. Tidwell, M. Pelletier, D. C. Look, and M. J. Holtzman
Virus-inducible expression of a host chemokine gene relies on replication-linked mRNA stabilization
PNAS, May 11, 1999; 96(10): 5680 - 5685.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
K. H. Noe, C. Cenciarelli, S. A. Moyer, P. A. Rota, and M. L. Shin
Requirements for Measles Virus Induction of RANTES Chemokine in Human Astrocytoma-Derived U373 Cells
J. Virol., April 1, 1999; 73(4): 3117 - 3124.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
M. R. Horton, S. Shapiro, C. Bao, C. J. Lowenstein, and P. W. Noble
Induction and Regulation of Macrophage Metalloelastase by Hyaluronan Fragments in Mouse Macrophages
J. Immunol., April 1, 1999; 162(7): 4171 - 4176.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
R. Lin, C. Heylbroeck, P. Genin, P. M. Pitha, and J. Hiscott
Essential Role of Interferon Regulatory Factor 3 in Direct Activation of RANTES Chemokine Transcription
Mol. Cell. Biol., February 1, 1999; 19(2): 959 - 966.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. R. Horton, C. M. McKee, C. Bao, F. Liao, J. M. Farber, J. Hodge-DuFour, E. Pure, B. L. Oliver, T. M. Wright, and P. W. Noble
Hyaluronan Fragments Synergize with Interferon-gamma to Induce the C-X-C Chemokines Mig and Interferon-inducible Protein-10 in Mouse Macrophages
J. Biol. Chem., December 25, 1998; 273(52): 35088 - 35094.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. R. Horton, M. D. Burdick, R. M. Strieter, C. Bao, and P. W. Noble
Regulation of Hyaluronan-Induced Chemokine Gene Expression by IL-10 and IFN-{gamma} in Mouse Macrophages
J. Immunol., March 15, 1998; 160(6): 3023 - 3030.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. E. Lane, V. C. Asensio, N. Yu, A. D. Paoletti, I. L. Campbell, and M. J. Buchmeier
Dynamic Regulation of {alpha}- and {beta}-Chemokine Expression in the Central Nervous System During Mouse Hepatitis Virus-Induced Demyelinating Disease
J. Immunol., January 15, 1998; 160(2): 970 - 978.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lokuta, M. A.
Right arrow Articles by Shin, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lokuta, M. A.
Right arrow Articles by Shin, H. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement